These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1992885)

  • 1. Emerging resistance to fluoroquinolones in staphylococci: an alert.
    Trucksis M; Hooper DC; Wolfson JS
    Ann Intern Med; 1991 Mar; 114(5):424-6. PubMed ID: 1992885
    [No Abstract]   [Full Text] [Related]  

  • 2. Lack of quinolone efficacy in two oncology patients with catheter-related infections caused by coagulase-negative staphylococci.
    Payne PD; Henry B; Smith EA; Baddour LM
    J Tenn Med Assoc; 1994 Jul; 87(7):285-7. PubMed ID: 8065132
    [No Abstract]   [Full Text] [Related]  

  • 3. Fluoroquinolone resistance in staphylococci: new challenges.
    Sanders CC; Sanders WE; Thomson KS
    Eur J Clin Microbiol Infect Dis; 1995; 14 Suppl 1():S6-11. PubMed ID: 7729471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-staphylococcal activity of temafloxacin, ciprofloxacin, ofloxacin and enoxacin.
    Barry AL; Fuchs PC
    J Antimicrob Chemother; 1991 Nov; 28(5):695-9. PubMed ID: 1663929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [In vitro activity of sparfloxacin against methicillin-resistant staphylococci].
    Wallrauch C; Voss A; Milatovic D; Braveny I
    Arzneimittelforschung; 1995 Jun; 45(6):723-5. PubMed ID: 7646580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibiotic resistance. Epidemiology of resistance in intensive therapy units (ITUs).
    Fraise AP
    J Med Microbiol; 1997 Jun; 46(6):447-9. PubMed ID: 9379471
    [No Abstract]   [Full Text] [Related]  

  • 7. In vitro study of staphylococci susceptibility to gatifloxacin.
    Tuchiluş C; Poiată A; Buiuc D
    Rev Med Chir Soc Med Nat Iasi; 2007; 111(2):516-9. PubMed ID: 17983195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibacterial activity of quinolones against coagulase-negative staphylococci and the quinolone resistance-determining region of the gyrA genes from six species.
    Takahata M; Yonezawa M; Matsubara N; Watanabe Y; Narita H; Matsunaga T; Igarashi H; Kawahara M; Onodera S; Oishi Y
    J Antimicrob Chemother; 1997 Sep; 40(3):383-6. PubMed ID: 9338491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quinolones in perspective.
    Neu HC
    J Antimicrob Chemother; 1990 Oct; 26 Suppl B():1-6. PubMed ID: 2258336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates.
    Roychoudhury S; Catrenich CE; McIntosh EJ; McKeever HD; Makin KM; Koenigs PM; Ledoussal B
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1115-20. PubMed ID: 11257024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of levofloxacin, ofloxacin and other quinolones against coagulase-negative staphylococci.
    Foleno BD; Lafredo SC; Fu KP
    Chemotherapy; 1993; 39(2):120-3. PubMed ID: 8458244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hospital staphylococci. Sensitivity of 100 strains to antibiotics].
    Debeaumont A; Duriez J
    Nouv Presse Med; 1972 Apr; 1(15):1017. PubMed ID: 5018883
    [No Abstract]   [Full Text] [Related]  

  • 13. Linezolid resistance in coagulase-negative staphylococci.
    Kelly S; Collins J; Davin M; Gowing C; Murphy PG
    J Antimicrob Chemother; 2006 Oct; 58(4):898-9; author reply 899-900. PubMed ID: 16854956
    [No Abstract]   [Full Text] [Related]  

  • 14. Resistant coagulase negative staphylococci from clinical specimen in and around Solapur (South Maharashtra).
    Kandle S; Ghtole MP; Kamale PB; Apama T; Jahagirdar VL; Yemul VL
    J Commun Dis; 2003 Jun; 35(2):132-5. PubMed ID: 15562961
    [No Abstract]   [Full Text] [Related]  

  • 15. Quinolone antimicrobial agents.
    Neu HC
    Annu Rev Med; 1992; 43():465-86. PubMed ID: 1580602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The rate of inducible clindamycin resistance and susceptibilities to other antimicrobial agents in staphylococci].
    Oğuz VA; Yapar N; Sezak N; Cavuş SA; Kurutepe S; Peksel H; Cakir N; Yüce A
    Mikrobiyol Bul; 2009 Jan; 43(1):37-44. PubMed ID: 19334378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relapse of Staphylococcus aureus septicemia due to the emergence ofa fluoroquinolone-resistant mutant].
    Chomarat M; Vital-Durand D; Gerbaud G
    Presse Med; 1990 Feb; 19(6):265. PubMed ID: 2138301
    [No Abstract]   [Full Text] [Related]  

  • 18. [Resistance spectrum of staphylococci at the Vienna general hospital (July to December 1991)].
    Aspöck C; Koller W; Rotter M; el Madani N; Seper E; Chizzali-Bonfadin C; Chizzali-Bonfadin C
    Wien Klin Wochenschr; 1994; 106(1):20-6. PubMed ID: 8135027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SYN987, SYN1193, and SYN1253, new quinolones highly active against gram-positive cocci.
    Kitzis MD; Goldstein FW; Ishida N; Acar JF
    J Antimicrob Chemother; 1995 Jul; 36(1):209-13. PubMed ID: 8537267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Staphylococcus epidermidis: emerging resistance and need for alternative agents.
    Raad I; Alrahwan A; Rolston K
    Clin Infect Dis; 1998 May; 26(5):1182-7. PubMed ID: 9597250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.